Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Abclon Inc. (174900:KRX), powered by AI.
Abclon Inc. is currently trading at ₩31,750. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Abclon Inc. on Alpha Lenz.
Abclon Inc.'s P/E ratio is -35.4.
“Abclon Inc. trades at a P/E of -35.4 (undervalued) with modest ROE of -39.9%. 3Y revenue CAGR of 11.4% highlights clear growth momentum.”
Ask for details →Abclon Inc. is a biotechnology company focused on the research and development of innovative therapeutic solutions. As a key player in the biotechnology sector, Abclon specializes in the creation of antibody-based treatments designed to address a variety of serious health conditions. These include cancer, autoimmune diseases, and infectious diseases. The company leverages cutting-edge technology in antibody engineering and proprietary platforms to advance its pipeline and develop novel biologics. By concentrating on highly specific and effective treatments, Abclon aims to provide options for conditions that are otherwise difficult to treat. The company's activities significantly impact the pharmaceutical and healthcare industries by driving forward medical research and offering potential new therapies. Abclon Inc.’s contributions are crucial in the context of global health, as they strive to bring about meaningful advancements in patient care and treatment outcomes.
“Abclon Inc. trades at a P/E of -35.4 (undervalued) with modest ROE of -39.9%. 3Y revenue CAGR of 11.4% highlights clear growth momentum.”
Ask for details →Abclon Inc. (ticker: 174900) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $633.5B.
The current price is ₩31,750 with a P/E ratio of -35.38x and P/B of 10.48x.
ROE is -39.86% and operating margin is -374.11%. Annual revenue is $4.7B.